J Stephen Mikita1, Jules Mitchel2, Nicolle M Gatto3, John Laschinger4, James E Tcheng5, Emily P Zeitler5, Arlene S Swern6, E Dawn Flick6, Christopher Dowd7, Theodore Lystig8, Sara B Calvert9. 1. Mikita Edge LLC, Salt Lake City, UT, USA. 2. Target Health LLC, New York, NY, USA. 3. Pfizer, New York, NY, USA. 4. U.S. Food and Drug Administration, Silver Spring, MD, USA. 5. Duke Clinical Research Institute, Durham, NC, USA. 6. Celgene Corporation, Summit, NJ, USA. 7. Cystic Fibrosis Foundation, Bethesda, MD, USA. 8. Medtronic, Minneapolis, MN, USA. 9. Clinical Trials Transformation Initiative, 200 Morris St, Durham, NC, 27701, USA. sara.calvert@duke.edu.
Abstract
BACKGROUND: Patient registries are organized systems that use observational methods to collect uniform data on specified outcomes in a population defined by a particular disease, condition, or exposure. Data collected in registries often coincide with data that could support clinical trials. Integrating clinical trials within registries to create registry-embedded clinical trials offers opportunities to reduce duplicative data collection, identify and recruit patients more efficiently, decrease time to database lock, accelerate time to regulatory decision-making, and reduce clinical trial costs. This article describes a project of the Clinical Trials Transformation Initiative (CTTI) intended to help clinical trials researchers determine when a registry could potentially serve as the platform for the conduct of a clinical trial. METHODS: Through a review of registry-embedded clinical trials and commentaries, semi-structured interviews with experts, and a multi-stakeholder expert meeting, the project team addressed how to identify and describe essential registry characteristics, practices, and processes required to for conducting embedded clinical trials intended for regulatory submissions in the United States. RESULTS: Recommendations, suggested practices, and decision trees that facilitate the assessment of whether a registry is suitable for embedding clinical trials were developed, as well as considerations for the design of new registries. Essential registry characteristics include relevancy, robustness, reliability, and assurance of patient protections. CONCLUSIONS: The project identifies a clear role for registries in creating a sustainable and reusable infrastructure to conduct clinical trials. Adoption of these recommendations will facilitate the ability to perform high-quality and efficient prospective registry-based clinical trials.
BACKGROUND:Patient registries are organized systems that use observational methods to collect uniform data on specified outcomes in a population defined by a particular disease, condition, or exposure. Data collected in registries often coincide with data that could support clinical trials. Integrating clinical trials within registries to create registry-embedded clinical trials offers opportunities to reduce duplicative data collection, identify and recruit patients more efficiently, decrease time to database lock, accelerate time to regulatory decision-making, and reduce clinical trial costs. This article describes a project of the Clinical Trials Transformation Initiative (CTTI) intended to help clinical trials researchers determine when a registry could potentially serve as the platform for the conduct of a clinical trial. METHODS: Through a review of registry-embedded clinical trials and commentaries, semi-structured interviews with experts, and a multi-stakeholder expert meeting, the project team addressed how to identify and describe essential registry characteristics, practices, and processes required to for conducting embedded clinical trials intended for regulatory submissions in the United States. RESULTS: Recommendations, suggested practices, and decision trees that facilitate the assessment of whether a registry is suitable for embedding clinical trials were developed, as well as considerations for the design of new registries. Essential registry characteristics include relevancy, robustness, reliability, and assurance of patient protections. CONCLUSIONS: The project identifies a clear role for registries in creating a sustainable and reusable infrastructure to conduct clinical trials. Adoption of these recommendations will facilitate the ability to perform high-quality and efficient prospective registry-based clinical trials.
Authors: Linda Peelen; Niels Peek; Evert de Jonge; Gert Jan Scheffer; Nicolette F de Keizer Journal: Int J Med Inform Date: 2006-07-07 Impact factor: 4.046
Authors: Sunil V Rao; Connie N Hess; Britt Barham; Laura H Aberle; Kevin J Anstrom; Tejan B Patel; Jesse P Jorgensen; Ernest L Mazzaferri; Sanjit S Jolly; Alice Jacobs; L Kristin Newby; C Michael Gibson; David F Kong; Roxana Mehran; Ron Waksman; Ian C Gilchrist; Brian J McCourt; John C Messenger; Eric D Peterson; Robert A Harrington; Mitchell W Krucoff Journal: JACC Cardiovasc Interv Date: 2014-08 Impact factor: 11.195
Authors: Jeffrey R Curtis; Nicole C Wright; Fenglong Xie; Lang Chen; Jie Zhang; Kenneth G Saag; Aseem Bharat; Joel Kremer; Stacey Cofield; Kevin Winthrop; Elizabeth Delzell Journal: Clin Trials Date: 2013-12-17 Impact factor: 2.486
Authors: Bina Ahmed; Winthrop D Piper; David Malenka; Peter VerLee; John Robb; Thomas Ryan; Michael Herne; William Phillips; Harold L Dauerman Journal: Circ Cardiovasc Interv Date: 2009-09-01 Impact factor: 6.546
Authors: L Ashley; H Jones; J Thomas; D Forman; A Newsham; E Morris; O Johnson; G Velikova; P Wright Journal: Br J Cancer Date: 2011-11-08 Impact factor: 7.640
Authors: Rishi Banerjee; Simon Erridge; Oliver Salazar; Nagina Mangal; Daniel Couch; Barbara Pacchetti; Mikael Hans Sodergren Journal: Ther Innov Regul Sci Date: 2021-11-08 Impact factor: 1.778